Osteoarthritis and Cartilage
Volume 16, Issue 9 , Pages 973-979 , September 2008

Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride

  • M. Meulyzer, D.V.M. (Dr.)

      Affiliations

    • Département des sciences cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St. Hyacinthe, Québec, Canada
    • ,
  • P. Vachon, D.V.M., Ph.D., Dipl. A.C.L.A.M. (Professor and Dr.)

      Affiliations

    • Département de biomédecine vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, St. Hyacinthe, Québec, Canada
    • ,
  • F. Beaudry, Ph.D. (Dr.)

      Affiliations

    • Département de biomédecine vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, St. Hyacinthe, Québec, Canada
    • ,
  • T. Vinardell, D.V.M. (Dr.)

      Affiliations

    • Département des sciences cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St. Hyacinthe, Québec, Canada
    • ,
  • H. Richard

      Affiliations

    • Département des sciences cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St. Hyacinthe, Québec, Canada
    • ,
  • G. Beauchamp, Ph.D. (Dr.)

      Affiliations

    • Faculté de Médecine Vétérinaire, Université de Montréal, St. Hyacinthe, Québec, Canada
    • ,
  • S. Laverty, M.V.B., M.R.C.V.S., Dipl. A.C.V.S., Dipl. E.C.V.S. (Professor and Dr.)

      Affiliations

    • Département des sciences cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St. Hyacinthe, Québec, Canada
    • Corresponding Author InformationAddress correspondence and reprint requests to: Sheila Laverty, M.V.B., M.R.C.V.S., Dipl. A.C.V.S., Dipl. E.C.V.S., Département des Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, C.P. 5000, St. Hyacinthe, Québec J2S 7C6, Canada.

Received 10 August 2007 ,Accepted 6 January 2008.

References 

  1. Bruyere O, Pavelka K, Rovati LC, Gatterova J, Giacovelli G, Olejarova M, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008;16:254–260
  2. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113–2123
  3. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251–256
  4. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford). 2002;41(3):279–284
  5. Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum. 2004;51(5):738–745
  6. Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, et al. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol. 2005;32(5):896–902
  7. Tiraloche G, Girard C, Chouinard L, Sampalis J, Moquin L, Ionescu M, et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum. 2005;52(4):1118–1128
  8. Reginster JY, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. Rheumatology (Oxford). 2007;46(5):731–735
  9. Altman RD, Abramson S, Bruyere O, Clegg D, Herrero-Beaumont G, Maheu E, et al. Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis Cartilage. 2006;14(10):963–966
  10. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808
  11. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555–567
  12. Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol. 2002;29(11):2407–2409
  13. Oke S, Aghazadeh-Habashi A, Weese JS, Jamali F. Evaluation of glucosamine levels in commercial equine oral supplements for joints. Equine Vet J. 2006;38(1):93–95
  14. Laverty S, Sandy JD, Celeste C, Vachon P, Marier JF, Plaas AH. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum. 2005;52(1):181–191
  15. Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage. 2007;15(7):764–772
  16. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2:CD002946
  17. Beaudry F, Vachon P. Determination of glucosamine in horse plasma by liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2008;22(1):1–4
  18. Bioanalytical method validation. In: Guidance for Industry. Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM); May 2001;http://www.fda.gov/cder/guidance/4252fnl.pdf
  19. Rowland M, Towser TN. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia: Lippincott Williams and Wilkins; 1995;
  20. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci. 2002;5(2):181–184
  21. Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos. 2002;23(6):217–225
  22. Du J, White N, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm Drug Dispos. 2004;25(3):109–116
  23. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittelforschung. 1993;43(10):1109–1113
  24. Wang SX, Laverty S, Dumitriu M, Plaas A, Grynpas MD. The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. Arthritis Rheum. 2007;56(5):1537–1548
  25. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005;13(12):1041–1049
  26. Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65(2):222–226
  27. Levick JR. Microvascular architecture and exchange in synovial joints. Microcirculation. 1995;2(3):217–233
  28. Moskowitz RW. Osteoarthritis: Diagnosis And Medical/Surgical Management. 4th edn.. Philadelphia: Wolters Kluwer Health/Lippincott Williams and Wilkins; 2007;
  29. Errecalde JO, Carmely D, Marino EL, Mestorino N. Pharmacokinetics of amoxycillin in normal horses and horses with experimental arthritis. J Vet Pharmacol Ther. 2001;24(1):1–6
  30. Firth EC, Klein WR, Nouws JF, Wensing T. Effect of induced synovial inflammation on pharmacokinetics and synovial concentration of sodium ampicillin and kanamycin sulfate after systemic administration in ponies. J Vet Pharmacol Ther. 1988;11(1):56–62
  31. Kraus VB, Huebner JL, Fink C, King JB, Brown S, Vail TP, et al. Urea as a passive transport marker for arthritis biomarker studies. Arthritis Rheum. 2002;46(2):420–427
  32. Neil KM, Orth MW, Coussens PM, Chan PS, Caron JP. Effects of glucosamine and chondroitin sulfate on mediators of osteoarthritis in cultured equine chondrocytes stimulated by use of recombinant equine interleukin-1beta. Am J Vet Res. 2005;66(11):1861–1869
  33. Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage. 2005;13(5):387–394
  34. Celeste C, Ionescu M, Robin Poole A, Laverty S. Repeated intraarticular injections of triamcinolone acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid. J Orthop Res. 2005;23(3):602–610
  35. van den Boom R, van de Lest CH, Bull S, Brama RA, van Weeren PR, Barneveld A. Influence of repeated arthrocentesis and exercise on synovial fluid concentrations of nitric oxide, prostaglandin E2 and glycosaminoglycans in healthy equine joints. Equine Vet J. 2005;37(3):250–256

1 This study was supported by the Groupe de Recherche en Médecine Équine du Québec, the Fonds du Centenaire, the Faculté de Médecine Vétérinaire of the Université de Montréal and the Canadian Arthritis Network.

PII: S1063-4584(08)00004-6

doi: 10.1016/j.joca.2008.01.006

Osteoarthritis and Cartilage
Volume 16, Issue 9 , Pages 973-979 , September 2008

Article Tools

* Image Usage & Resolution